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Background: Clinical trials are essential to the advancement of cancer treatment but fewer than 5% of adult cancer patients
enroll in a trial. A commonly cited barrier to participation is the lack of understanding about clinical trials.
Objective: Since the internet is a popular source of health-related information and YouTube is the second most visited website
in the world, we examined the content of the top 115 YouTube videos about clinical trials to evaluate clinical trial information
available through this medium.
Methods: YouTube videos posted prior to March 2017 were searched using selected keywords. A snowballing technique was
used to identify videos wherein sequential screening of the autofill search results for each set of keywords was conducted. Video
characteristics (eg, number of views and video length) were recorded. The content was broadly grouped as related to purpose,
phases, design, safety and ethics, and participant considerations. Stepwise multivariable logistic regression analysis was conducted
to assess associations between video type (cancer vs noncancer) and video characteristics and content.
Results: In total, 115 videos were reviewed. Of these, 46/115 (40.0%) were cancer clinical trials videos and 69/115 (60.0%)
were noncancer/general clinical trial videos. Most videos were created by health care organizations/cancer centers (34/115,
29.6%), were oriented toward patients (67/115, 58.3%) and the general public (68/115, 59.1%), and were informational (79/115,
68.7%); altruism was a common theme (31/115, 27.0%). Compared with noncancer videos, cancer clinical trials videos more
frequently used an affective communication style and mentioned the benefits of participation. Cancer clinical trial videos were
also much more likely to raise the issue of costs associated with participation (odds ratio [OR] 5.93, 95% CI 1.15-29.46) and
advise patients to communicate with their physician about cancer clinical trials (OR 4.94, 95% CI 1.39-17.56).
Conclusions: Collectively, YouTube clinical trial videos provided information on many aspects of trials; however, individual
videos tended to focus on selected topics with varying levels of detail. Cancer clinical trial videos were more emotional in style
and positive in tone and provided information on the important topics of cost and communication. Patients are encouraged to
verify and supplement YouTube video information in consultations with their health care professionals to obtain a full and accurate
picture of cancer clinical trials to make an adequately informed decision about participation.
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Introduction
The release of new cancer treatments to market has outpaced
all other therapeutic areas [1], with the introduction of 70
oncology treatments for more than 20 different tumor types
over the past 5 years alone [2]. Bringing a new cancer treatment
to the clinical setting is a complex process that extends over
many years from the initial discovery and development in the
laboratory through Food and Drug Administration (FDA)
approval for use [3]. Integral to this process are the heavily
FDA-regulated clinical trials that rigorously determine the safety
and effectiveness of new and promising treatments among
humans in an experimental setting [4].
Clinical trials are designed to answer specific research questions
and are, thus, governed by strict protocols and eligibility criteria.
Informed consent documents, which provide potential
participants with detailed information about the purpose of the
study, procedures to be performed, potential harms and benefits
of the experimental agents used, and the voluntary nature of
participation, are federally mandated to ensure that participants
make informed decisions regarding enrollment. Much of the
information presented to a patient is complex, incorporating
translational research, biomarker selection, and sophisticated
study designs into trials [5], but the level of health literacy
remains low in the adult US population [6]. Fewer than 5% of
adult cancer patients enroll in clinical trials [7], the most
commonly cited barriers being lack of awareness or knowledge
regarding clinical trials [8-14] and the reluctance to be
randomized [15-19].
In one study, 92% of cancer patients reported the internet as the
resource that empowered them when making treatment decisions
and provided them with information with which to engage their
physicians in discussion [20]. Cancer patients also use the
internet to seek clarification, more detailed information, or
reassurance about what was learned after a clinical encounter
about clinical trials [21,22]. Much of the clinical trial
information available online has been characterized as variable
in quality with poor readability [23]. While clinical trial search
tools are relatively easy to locate on the internet using various
search engines, both content and functionality were also highly
variable, and users needed a fair amount of knowledge about
their condition and good web navigation skills to access the
relevant information [24]. In a study that simulated the search
for treatments of four common cancers by naïve cancer patients
without clinical trial knowledge, only 85% of cancer-treatment
sites mentioned clinical trials on the landing page and only 68%
provided links to trials [23]. Another study that evaluated the
navigability of comprehensive cancer center websites to clinical
trial information observed that clinical trial content is narrow
in scope with trial descriptions written at a college reading level,
thereby limiting understanding for the average user [25]. When
the written word proves to be challenging, consumers may turn
to video-based information.
First introduced in 2005, YouTube is the second most visited
website worldwide, and it has become an increasingly important
medium through which health information is exchanged between
and shared by consumers and health care professionals,
government and nongovernment agencies, and industries [26].
Recent statistics indicate that currently, 300 hours of videos are
uploaded to YouTube every minute and almost 5 billion videos
are watched by 30 million visitors every day [27]. Despite the
extensive reach and pervasive use of YouTube videos, little is
known about videos related to cancer clinical trials; thus, the
aim of this study was to evaluate the content of the most widely
viewed YouTube videos related to clinical and cancer clinical
trials.
Methods
YouTube videos posted prior to March 2017 were searched for
using the keywords “clinical trial(s)” (426,000 videos), “cancer
clinical trial(s)” (352,000 videos), “clinical trials cancer”
(611,000 videos), and “oncology clinical trial” (619,000 videos).
To reduce bias introduced in the display of videos by the search
engine due to the location and search history of the study
computer, searches were conducted using the incognito mode
of Google Chrome in a single day, with results captured for
later assessment [26]. A snowballing technique was used to
select videos for review wherein sequential screening of the
autofill search results for each set of keywords was conducted.
A total of 25 search term options were initially identified (Figure
1); 6 search term options were deemed irrelevant and excluded.
The first 30 videos from each of the 19 remaining search term
options were recorded; duplicate videos were removed, yielding
291 cancer clinical trial videos. YouTube uses a complex
algorithm to rank video quality that is based on the duration the
video has been watched. Longer viewer time indicates that the
video is most likely appropriate for the search terms employed,
which results in a higher ranking and greater likelihood of the
video appearing on top of a search list [28].
Videos with <200 views (n=77) and those deemed irrelevant
(n=80) were removed. Of the remaining 134 videos, additional
19 videos were found to be irrelevant upon viewing and were
excluded from the final analysis. The remaining 115 videos
were reviewed by 4 independent reviewers (GCH, SAM, KMS,
and MB). Interrater reliability of the video characteristics and
content-related variables, excluding the number of views, video
length, and “thumbs up” and “thumbs down” was assessed by
a fifth reviewer (CHB) and was found to be high among a
randomly selected 10% sample (Cohen kappa=0.85).
JMIR Cancer 2018 | vol. 4 | iss. 1 | e10060 | p. 2http://cancer.jmir.org/2018/1/e10060/
(page number not for citation purposes)
Hillyer et alJMIR CANCER
XSL•FO
RenderX
Figure 1. Keywords and search terms. Asterisk indicates terms considered irrelevant and excluded.
The following video characteristics were assessed: number of
views, length of the video in minutes, year published, country
of origin, video source (nonprofit organization, health care
provider/organization or cancer center, school/educational
organization, pharmaceutical or biotech company, clinical
research organization, or other), and YouTube video category
(nonprofits and activism, science and technology, education,
people and blogs, or other). Style of communication was
categorized as affective versus cognitive.
Videos were coded as affective in style if the content was
presented verbally with overt positive or negative emotion that
was persuasive in nature, whereas videos in which the content
was delivered nonpersuasively, verbally or nonverbally, and
without overt emotion were coded as cognitive in style. Also
evaluated was the tone of the video (positive, negative, or
neutral). Themes arising in the video (altruism/positive
emotions, risks and dangers of clinical trials, advancing science,
importance of volunteering for clinical trials, and other), the
intended audience (patients, general public, caregivers, health
care professionals, students, and research personnel assessed
as to whom the information was being addressed), and the
manner of presentation (lecture/course format/webinar,
interview, testimonial, advertisement for paid participation, and
other) were also evaluated. Viewer perceptions concerning the
videos were also captured by assessing the “thumbs up,”
“thumbs down,” and comment counts. Using the National
Cancer Institute (NCI) Clinical Trials Information for Patients
and Caregivers [29] series of documents as the reference
standard, the content of each video was grouped a priori into
five broad categories: clinical trial purpose, trial phases, study
design, safety and ethics, and participant considerations.
Reviewers derived the themes embedded in the content
throughout the video viewing process; categorization of themes
(eg, altruism/positive emotions, risks/dangers, advancing
science, importance of volunteering, and other) was based on
reviewer consensus.
Descriptive analyses, including calculation of frequency
distributions, means (SD), and ranges, were performed. To
assess video characteristics and content differences between
videos for cancer clinical trials and clinical trials in general or
videos with a focus on a disease other than cancer, univariable
analyses using chi-square test for categorical variables and
analysis of variance for continuous variables were conducted.
Stepwise multivariable logistic regression models, controlling
for the year of publication, were constructed to assess the
associations between video type (cancer vs noncancer) and
variables with P values <.05 in the univariable analysis,
controlling for the year of upload. All analyses were performed
using IBM SPSS (version 24) [30]. Institutional review boards
of each author’s respective institution deemed nonhuman subject
research exempted from review.
Results
The 115 videos related to clinical trials were viewed by
approximately 11 million viewers with a mean number of 94,360
(SD 827,883) views each (Table 1).
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Table 1. Characteristics of YouTube videos related to clinical trials.
P valueNoncancer related (n=69)Cancer related (n=46)Total (n=115)Variable
9,375,9741,475,39210,851,366Number of views
.20135,883.7 (1,059,819.2)32,073.7 (180,025.0)94,359.7 (827,883.4)Mean (SD)
216-8,810,958226-1,223,520216-8,810,958Range
Length of video (minutes)
.038.8 (13.3)6.6 (6.9)7.95 (11.2)Mean (SD)
0.6-61.00.8-35.90.57-61.0Range
.48Year published, n (%)
7 (10.1)9 (19.6)16 (13.9)2005-2010
19 (27.5)10 (21.7)29 (25.2)2011-2012
25 (36.2)14 (30.4)39 (33.9)2013-2014
18 (26.1)13 (28.3)31 (27.0)2015-2016
.09Country of origin, n (%)
53 (76.8)41 (89.1)94 (81.7)United States
16 (23.2)5 (10.9)21 (18.3)Other
<.001Video source, n (%)
12 (17.4)10 (21.7)22 (19.1)Nonprofit organization
11 (15.9)23 (50.0)34 (29.6)Health care organization/cancer center
7 (10.1)0 (0.0)7 (6.1)School/educational organization
7 (10.1)1 (2.2)8 (7.0)Pharma/biotech
16 (23.2)3 (6.5)19 (16.5)CROa/recruitment agency
16 (23.2)9 (19.6)25 (21.7)Other
.47YouTube category, n (%)
11 (15.9)13 (28.3)24 (20.9)Nonprofits & activism
27 (39.1)14 (30.4)41 (35.7)Science & technology
20 (29.0)10 (21.7)30 (26.1)Education
5 (7.2)5 (10.9)10 (8.7)People & blogs
6 (8.7)4 (8.7)10 (8.7)Other
Communication style, n (%)
.0424 (34.8)25 (54.3)49 (42.6)Affective
.2950 (72.5)29 (63.0)79 (68.7)Cognitive
.04Tone, n (%)
39 (56.5)35 (76.1)74 (64.3)Positive
5 (7.2)4 (8.7)9 (7.8)Negative
25 (36.2)7 (15.2)32 (27.8)Neutral
Theme, n (%)
.01613 (18.8)18 (39.1)31 (27.0)Altruism/positive emotions
1.007 (10.1)4 (8.7)11 (9.6)Risks/dangers
.484 (5.8)5 (10.9)9 (7.8)Advancing science
.637 (10.1)6 (13.0)13 (11.3)Importance of volunteering
.317 (10.1)2 (4.3)9 (7.8)Other
Intended Audience, n (%)
<.00130 (43.5)37 (80.4)67 (58.3)Patients
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P valueNoncancer related (n=69)Cancer related (n=46)Total (n=115)Variable
.3943 (62.3)25 (54.3)68 (59.1)General public
.560 (0.0)1 (2.2)1 (0.9)Caregivers
.479 (13.0)4 (8.7)13 (11.3)Health care professionals
.086 (8.7)0 (0.0)6 (5.2)Students
.405 (7.2)1 (2.2)6 (5.2)Research personnel
Presentation, n (%)
.5343 (62.3)26 (56.5)69 (60.0)Lecture/course/webinar
.8310 (14.5)6 (13.0)16 (13.9)Interview
.04814 (20.3)17 (37.0)31 (27.0)Testimonial




.111584.0 (12806.1)33.3 (132.9)963.7 (9920.3)Mean (SD)
0-10,64150-8970-10,6415Range
Thumbs down
.11463.01 (3825.2)18.0 (116.1)285.1 (2963.3)Mean (SD)
0-31,7770-7880-31,777Range
Comments
.10164.6 (1302.9)1.5 (3.4)99.4 (1009.4)Mean (SD)
0-10,8240-150-10,824Range
aCRO: clinical research organization.
Forty-six of 115 (40.0%) videos discussed cancer clinical trials
versus 69/115 (60.0%) that either focused on other diseases (eg,
Parkinson’s disease) or were general discussions of clinical
trials, not related to any specific disease. The mean length of a
video was approximately 8 min (SD 11.2) and the majority
(94/115, 81.7%) of the videos were produced in the United
States. Videos created by health care organizations, including
cancer centers, predominated (34/115, 29.6%), and many were
posted under the “science and technology” theme of YouTube.
Overall, videos were oriented toward patients (67/115, 58.3%)
and the general public (68/115, 59.1%), tended to be cognitive
(79/115, 68.7%) in nature, and were presented as a
lecture/course/webinar (69/115, 60%). The most popular theme
among clinical trial videos was altruism and other positive
emotions associated with clinical trial participation (31/115,
27.0%) followed by the importance of volunteering for trials
(13/115, 11.3%).
Compared with noncancer-related videos, cancer clinical trial
videos were shorter in length (6.6 vs 8.8 min, P=.03) and were
more often created by health care organizations (23/46, 50.0%
vs 11/69, 15.9%, P<.001). More than half of the cancer videos
used an affective approach compared to about one-third of
noncancer videos (P=.04) and, compared to noncancer videos,
more often expressed a positive tone (35/46, 76.1% vs 39/69,
56.5%, P=.04) toward clinical trials and focused on altruism
and other positive emotions (18/46, 39.1% vs 13/69, 18.8%,
P=.016). Compared with only 43.5% (30/69) of noncancer
videos (P<.001), 80% (37/46) of cancer videos were geared
toward a patient population and were most often presented as
testimonials (patient and physician; 37% (17/46) vs 20.3%
(14/69), P=.048).
With regard to the content, the most commonly mentioned item
was the purpose of a clinical trial (62/115, 53.9%), followed by
the fact that clinical trials are conducted in phases (44/115,
38.3%), information about specific phases (Phase I=46/115,
40.0%, Phase II=37/115, 32.2%, and Phase III=40/115, 34.8%),
there is eligibility criteria for entering a trial (37/115, 32.2%),
and that there are benefits to participating in a clinical trial
(38/115, 33.0%; Table 2). Cancer-related clinical trial videos
more often mentioned that Phase I studies evaluate how the
drug effects the body and are used to determine potential side
effects (4/46, 8.7% vs 0/69, 0%, P=.02) and that they may be
offered in cases when no standard treatment options exist (5/46,
10.9% vs 0/69, 0%, P=.009) compared with noncancer-related
videos. Cancer-related videos also differed from
noncancer-related videos in that cancer-related videos more
frequently mentioned the benefits of clinical trial participation,
such as better care and monitoring (21/46, 45.7% vs 11/69,
15.9%, P<.001), participants could be the first to benefit from
an experimental treatment if it works (19/46, 41.3% vs 7/69,
10.1%, P<.001), and their participation could very well help
others in the future (20/46, 43.5% vs 13/69, 18.8%, P=.004).
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Table 2. Clinical trial YouTube video content.
P valueNoncancer related (n=69), n (%)Cancer related (n=46), n (%)Total (n=115), n (%)Variable
Purpose
.2234 (49.3)28 (60.9)62 (53.9)Mentions purpose in general
.3210 (14.5)10 (21.7)20 (17.4)Test new drugs/devices in human subjects
.318 (11.6)2 (4.3)10 (8.7)Determine a safe drug dose
.654 (5.8)1 (2.2)5 (4.3)Determine drug efficacy
1.002 (2.9)1 (2.2)3 (2.6)Test a research question
Trial phases
.5328 (40.6)16 (34.8)44 (38.3)Mentions there are phases in general
.8828 (40.6)18 (39.1)46 (40.0)Phase I
.9320 (29.0)13 (28.3)33 (28.7)Determine dosing
.096 (8.7)9 (19.6)15 (13.0)Assess safety
.5710 (14.5)5 (10.9)15 (13.0)Determine method of administration
.0918 (23.1)6 (13.0)24 (20.9)Small sample size
1.004 (5.8)2 (4.3)6 (5.2)Healthy volunteers
1.002 (2.9)1 (2.2)3 (2.6)Compensation for participation
.020 (0.0)4 (8.7)4 (3.5)How the drug affects the body/side effects
.0090 (0.0)5 (10.9)5 (4.3)When no other standard treatment options are
available
.9322 (31.9)15 (32.6)37 (32.2)Phase II
.8018 (26.1)13 (28.3)31 (27.0)Determine effect on disease course
.04516 (23.2)4 (8.7)20 (17.4)<100 sample size
.6923 (33.3)17 (37.0)40 (34.8)Phase III
.1716 (23.2)16 (34.8)32 (27.8)Compare to standard treatment
.2217 (24.6)7 (15.2)24 (20.9)>100 sample size
.1910 (14.5)3 (6.5)13 (11.3)Phase IV
1.005 (7.2)3 (6.5)8 (7.0)Postmarketing testing for side effects
Study design
.5416 (23.2)13 (28.3)29 (25.2)Randomized controlled trial
.739 (13.0)5 (10.9)14 (12.2)Reduce bias
.2612 (17.4)12 (26.1)24 (20.9)Control group
.8514 (20.3)10 (21.7)24 (20.9)Interventional group
.4411 (15.9)5 (10.9)16 (13.9)Blinding
.3617 (24.6)8 (17.4)25 (21.7)Placebo trial
.2417 (24.6)16 (34.8)33 (28.7)Research team
Safety and ethics
1.005 (7.2)4 (8.7)9 (7.8)FDAa regulatory process
.768 (11.6)4 (8.7)12 (10.4)Written protocols/strict guidelines
.3720 (29.0)17 (37.0)37 (32.2)Eligibility criteria
.3920 (29.0)10 (21.7)30 (26.1)Protection of safety
.768 (11.6)4 (8.7)12 (10.4)IRBb
.392 (2.9)3 (6.5)5 (4.3)DSMBc
.8411 (15.9)8 (17.4)19 (16.5)FDA
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P valueNoncancer related (n=69), n (%)Cancer related (n=46), n (%)Total (n=115), n (%)Variable
1.002 (2.9)2 (4.3)4 (3.5)Ethical conduct of research
.8021 (30.4)13 (28.3)34 (29.6)Informed consent
.2915 (21.7)14 (30.4)29 (25.2)Explanation of purpose, procedures, benefits,
and harms
.1215 (21.7)16 (34.8)31 (27.0)Voluntary nature of participation
.139 (13.0)11 (23.9)20 (17.4)Ability to withdraw at any time
Participant considerations
Potential benefits
.1219 (27.5)19 (41.3)38 (33.0)Mentions benefits in general
<.00111 (15.9)21 (45.7)32 (27.8)Better care and monitoring
<.0017 (10.1)19 (41.3)26 (22.6)First to benefit if treatment works
.00413 (18.8)20 (43.5)33 (28.7)Help others in the future
Potential risks
.4819 (27.5)10 (21.7)29 (25.2)Mentions risks in general
1.002 (2.9)2 (4.3)4 (3.5)Not always better than standard treatment
.4710 (14.5)9 (19.6)19 (16.5)No guarantee of effectiveness
.2513 (18.8)5 (10.9)18 (15.7)Unknown side effects
.0024 (5.8)12 (26.1)16 (13.9)Costs associated with participation
<.0018 (11.6)24 (52.2)32 (27.8)Communication with physician
.033 (4.3)8 (17.4)11 (9.6)Communication with family
.015 (7.2)11 (23.9)16 (13.9)Quality of life
aFDA: Food and Drug Administration.
bIRB: institutional review board.
cDSMB: Data Safety Monitoring Board.
Additionally, the cost associated with participation (12/46,
26.1% vs 4/69, 5.8%, P=.002), the importance of communication
with one’s doctor (24/46, 52.2% vs 8/69, 11.6%, P<.001) and
family (8/46, 17.4% vs 3/69, 4.3%, P=.03), and the quality of
life (11/46, 23.9% vs 5/69, 7.2%, P=.01) were all mentioned
more often in cancer-related videos than in noncancer-related
videos.
Results of the multivariable regression analysis demonstrated
that compared with noncancer clinical trial videos, videos related
to cancer clinical trials are much more likely to have been
created by health care organizations, including cancer centers
(odds ratio [OR] 5.95, 95% CI 1.70-20.88), to mention the costs
associated with clinical trial participation (OR 5.93, 95% CI
1.15-29.46) and to advise patients to communicate with their
physician about cancer clinical trials (OR 4.94, 95% CI
1.39-17.56; Table 3).
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Table 3. Video characteristics and content associated with cancer clinical trial YouTube videos.





ReferenceOther (school, CROa, education, other)













.212.30 (0.63-8.41)Better care and monitoring
.212.19 (0.65-7.41)First to benefit if treatment works
.0335.83 (1.15-29.46)Costs associated with participation
.0134.94 (1.39-17.56)Communication with physician
.981.03 (0.14-7.63)Communication with family
.302.15 (0.50-9.20)Quality of life
aCRO: clinical research organization.
Discussion
Principal Findings
Our review of the 115 top viewed YouTube videos revealed
that a large proportion of these videos are devoted to cancer
clinical trials. Overall, clinical trial videos convey information
that is aimed at both patients and the general population
audiences. The majority of the videos presented the viewer with
the overall purpose of a clinical trial and many discussed the
phases of clinical trials and the fact that criteria are used to
determine a patient’s eligibility for enrollment. Beyond these
topics, the video content varied widely, with most touching
upon selected topics (eg, phases of clinical trials, federal
regulations, informed consent or benefits of enrollment, and the
importance of communication with a physician). Interestingly,
none discussed the concept of clinical equipoise.
Cancer clinical trial videos were more positive in tone and more
frequently used an affective communication style. They tended
to emphasize altruism, the importance of volunteering to
participate in a trial, and the benefits of participation more so
than did non-cancer videos. Further, cancer clinical trial videos
were nearly six times as likely to be created by a health care
organization or a cancer center and were much more likely than
noncancer trial videos to communicate practical information
about clinical trial participation costs and to encourage dialogue
with one’s physician.
Limitations
Much attention was taken in the selection of the videos reviewed
in this study to represent the most commonly viewed YouTube
videos about clinical trials however, selecting the top 30 videos
with greater than 200 views may have introduced a selection
bias. Since the YouTube video ranking algorithm places videos
with longer user viewing times at the top of the list and overlap
was found in the videos in the top 30 for the search terms, our
inclusion criteria likely captured the most widely viewed
YouTube videos related to clinical trials. Further, we postulated
that any bias introduced by the algorithm would similarly
influence the videos displayed when a consumer uses the same
search term and that the impact of less-viewed videos would
be minimal. Despite using search terms specific to cancer
clinical trials, we found that a large proportion of clinical trial
videos were not related to cancer. While this was an unexpected
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finding, a consumer using our search terms would likely have
the same experience. Whether or not viewers were engaged for
the full duration of any video is unknown as 30 seconds of
YouTube watching is considered a “viewing” [31]. This study
is also limited in that it was cross-sectional in design and is
further compounded by the fact that new videos are continually
being uploaded on YouTube. Finally, this study focused solely
on English language videos.
Comparison With Prior Work
To date, no other study has evaluated the contents of YouTube
videos regarding clinical trials. More than 800 peer-reviewed
publications reporting on the quality and content of YouTube
videos relating to public health topics ranging from anorexia
[32] to Zika virus [33] now exist, which is cause for concern
regarding the power of this medium to communicate information
accurately and responsibly to the general public. The decision
to take part in a cancer clinical trial is a complex one, and the
most common barrier to participation is lack of knowledge about
cancer clinical trials [33]. Two separate studies found that the
internet and media are the primary sources for learning about
clinical trials [34] and that the information “read, saw, or heard”
about a study was a major influence on the decision to
participate. Further evidence supports that seeking information
about one’s illness can be viewed as a key coping strategy,
which may lead to health-promotive activity and facilitate
psychosocial adjustment to illness [35]. Use of the internet as
a source of health-related information, however, has been
likened to drinking from a fire hose and not knowing the source
of the water [36], a sentiment that can easily be applied to
YouTube video viewing. Because there exists no arbiter of the
truth or accuracy of the material posted on YouTube, many
question both the credibility and accuracy of the information
and find that the content is influenced by perspectives of the
video source [37-42]. Currently, the NCI acknowledges the
importance of social media as a source of health-related
information, and through its Cancer Moonshot Initiative, seeks
to leverage this platform to provide patients with reliable
information by developing a social media best practices toolkit.
Information learned in this study showed that the majority of
the clinical trial information communicated was accurate, as
determined using NCI information for comparison [29] and was
conveyed in a positive and compassionate manner. The coverage
of topics however, was spotty, and the sufficiency and quality
of information was lacking many times.
Conclusions
Overall, YouTube clinical trial videos provided information on
many aspects of clinical trials, particularly cancer clinical trials.
Few covered the full range of concepts needed to make an
informed decision about participation; the majority focused on
selected topics and provided varying levels of detail, leaving
the viewer with an incomplete view of key concepts and partially
informed. Given the abundance of clinical trial videos and
relative ease of access to this information, care must be taken
by patients and their families to verify and supplement YouTube
video information with consultations with their healthcare
professional to obtain a full and accurate picture of cancer
clinical trials, thus, to make an adequately informed decision
about participation.
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